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Abstract 
Background: Streptococcus group B (GBS) or Streptococcus agalactiae is typically associated with neonatal 
disease and infection in pregnant women. Mortality of GBS sepsis in neonates is over 50% and is particularly 
high in preterm infants. GBS also causes invasive infection in pregnant and non-pregnant women including 
urinary tract infection (UTI). Penicillin-derived antibiotics remained as choice drugs for treatment of GBS 
infection; however, Erythromycin and Clindamycin are useful in cases of allergic to Penicillin. The aim of this 
study was to investigate the resistance to Erythromycin and Clindamycin, especially inducible Clindamycin 
resistance, in GBS isolated from urinary samples of women who attended medical offices in Tehran, Iran. 
Materials and Methods: This study was conducted on 5000 urine samples from Jan. 2011 to Oct. 2012 that 
104 GBS were isolated. The isolates were identified as GBS using laboratory criteria. Antimicrobial 
susceptibility test was done by Erythromycin disk 15µg and Clindamycin disk 2µg for observation inducible 
resistant D-zone test by double-disk diffusion method with Erythromycin and adjacent Clindamycin. 
Results: Among the 5000 urine samples 104 (2.08%) were Beta hemolytic GBS. Of the 104 isolated GBS, 22 
(21.2%) were resistance, 24 (23%) were intermediate, and 58 (55.8%) were susceptible to Erythromycin; 
however, 24 (23%) were resistance, 5 (4.8%) were intermediate, and 75 (72.2%) were susceptible to 
Clindamycin. Of the 22 Erythromycin-resistant isolates, 10 (9.5% in total GBS isolated) displayed the D 
zone; it means they have inducible Erythromycin resistant to Clindamycin. 
Conclusion: Various studies in other countries report lower rates of inducible Clindamycin resistance; it 
indicates the use of more macrolides in the treatment of UTI. 
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Group B Streptococcus (GBS) or Streptococcus 
agalactiae can be cause of infection in neonates, 
pregnant women, and non-pregnant adults who those 
are elderly persons with chronic medical illness
1,2
. 
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These infections have frequently been seen since 
1970s. According to recent studies GBS infections 
have a high rate in developed countries
3,4
. Group B 
β-hemolytic streptococcus infection is an important 
cause of early-onset neonatal morbidity and 
mortality
5
. Mortality of GBS sepsis in neonates is 
over 50% and is especially high in preterm infants
6
. 
GBS commonly colonizes the female genitourinary 
tract (10–40% of pregnant women), which is the 
usual source of early-onset neonatal infection
5
. Also 
Streptococcus agalactiae is a component of human 
intestinal and genitourinary microflora
7
. 
Transmission from a colonized pregnant woman to 
her neonate occurs via the ascending route during 
labor and delivery. Administration of intrapartum 
antimicrobial prophylaxis (IAP) to colonized women 
has resulted in a striking decline in cases of early-
onset and maternal GBS disease
1
. GBS are usually 
responsible for sepsis and meningitis in the first 
weeks of life. In spite of regional variations, the 
incidence for GBS-related neonatal meningitis and 
sepsis is 0.5-3 per 1000 live births
3
.  
GBS is identified as an infectious agent of invasive 
disease in non-pregnant adults especially those 
underlying conditions such as diabetes mellitus, 
malignancy, or liver disease
4
. The incidence of 
invasive GBS infection in non-pregnant adults has 




GBS also cause urinary tract infections (UTIs), 
which encompass asymptomatic bacteriuria, cystitis, 
pyelonephritis, urethritis, and urosepsis. GBS 
asymptomatic bacteriuria is particularly common 
among pregnant women; however, those most at risk 
for cystitis due to GBS are the elderly and 
immunocompromised individuals. Predisposing 
factors for GBS UTI may include diabetes mellitus 
and chronic renal failure
1
. Between 5% and 23% of 
nonpregnant adults with invasive GBS disease 
present with a urinary tract infection
8
. Clinical 
manifestations of GBS infection in adults are 
numerous and quite varied. Because group B 
streptococci may colonize skin and mucosal surfaces 
and may be isolated from infected sites along with 
other virulent organisms, their role in pathogenesis 
has often been questioned. However, studies of 
invasive GBS infection in which the organisms are 
isolated from normally sterile sites such as blood or 
CSF provide direct evidence that group B streptococci 




The study subjects were women patients who 
presenting to different medical offices and experienced 
clinical and microbiological assessments for urinary 
tract infection (UTI) because of symptoms indicating 
infection or as part of routine patient screening. In this 
study 5000 urine samples was examined to obtain 
Streptococcus agalactiae between January 2011 and 
October 2012 in microbiology laboratory of 
paramedical faculty of Shahid Beheshti University of 
Medical Sciences in Tehran. The isolates were 
identified as GBS, if they were: 1) Beta hemolytic 
catalase-negative, 2) gram-positive cocci resistant both 
to Trimethoprim Sulphamethoxazole (SXT) and 
Bacitracin disks on Mueller Hinton blood (MHB) agar 
medium, 3) positive hippurate hydrolysis test, and 4) 
positive CAMP test. Antimicrobial susceptibility test 
was done by Erythromycin disk 15µg and 
Clindamycin disk 2µg for observation inducible 
resistant D-zone test by double-disk diffusion method 
with Erythromycin and adjacent Clindamycin. 
Antimicrobial susceptibility test by Erythromycin disk 
15µg and Clindamycin disk 2µg (from Rosco 
company) performed on Mueller–Hinton agar plates 
with 5% defibrinated sheep blood and incubated for 24 
hours in 35˚C with 5% CO2 for all confirmed GBS 
isolates (104 samples), then interpreted according to 
the Clinical and Laboratory Standards Institute (CLSI) 
in 2011. Erythromycin-resistant, Clindamycin-
susceptible isolates were appraised for inducible 
Clindamycin resistance by the D-zone test. For 
observation inducible resistant D-zone test were used 
double-disk diffusion method with Erythromycin and 
adjacent Clindamycin. According to standards of CLSI 
to detect inducible Clindamycin resistance isolates by 
disk diffusion method, the D-zone test was performed 
with a 12mm edge-to-edge spacing between 
Erythromycin and Clindamycin discs. Appearance of 
flattened configuration of the Clindamycin zone of 
inhibition adjacent to the Erythromycin disk shows a 
positive test. 
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Results 
Among the 5000 urine samples, 104 (2.08%) were 
detected as Group B β-hemolytic streptococcus. 
According to the CLSI recommendations about 
antimicrobial susceptibility and D zone tests, 
antimicrobial susceptibility test by Clindamycin and 
Erythromycin disks was performed for the 104 GBS 
isolated. 22 (21.2%) isolates were resistance, 24 
(23%) isolates were intermediate and 58 (55.8%) 
isolates were susceptible to Erythromycin. 24 (23%) 
isolates were resistance, 5 (4.8%) isolates were 
intermediate and 75 (72.2%) isolates were 
susceptible to Clindamycin (Table 1). The double 
disk diffusion test for inducible Clindamycin 
resistance was performed on all isolates resistant to 
Erythromycin and susceptible to Clindamycin. 
Inducible Clindamycin resistance by Erythromycin 
was displayed by presenting the appearance of a “D” 
around Clindamycin disk on plate in 10 (9.5% in 
total GBS isolated) isolates, so these cases showed an 
positive D zone test (iMLSB phenotype ) (Figure 1). 
Also resistance to both Erythromycin and 
Clindamycin disks (cMLSB phenotype) (Figure 2) 
was indicated in 11 (10.5% in total GBS isolated) 
isolates and just one (1% in total GBS isolated) case 
showed a Erythromycin-resistant and Clindamycin-
susceptible without D zone (M phenotype) (Figure 3) 
(Table 2). 
Discussion 
Penicillin and Ampicillin are the choice drugs for 
treatment of β-hemolytic streptococcal infections
9
. In 
patients with penicillin allergies or a lack of clinical 
response, alternative therapies, such as macrolides 
(e.g., Erythromycin), Lincosamides (e.g., 
Clindamycin) are often considered for treatment of 
infections. Group B streptococci are susceptible to 
Ampicillin, Penicillin, and Cefazolin, but may be 
resistant to Clindamycin and/or Erythromycin
9-11
. In a 
research in Tehran in 2010, among the 498 Group B 
streptococci isolates taken from adult women’s urine 
cultures, 24.2% and 16.8% isolates were resistance to 
Erythromycin and Clindamycin, respectively
4
.  
Resistance frequencies currently range from 6% to 
21% for Clindamycin and 12% to 29% for 
Erythromycin in the United States, while other 
countries report higher rates
12
. 
GBS colonization of the urinary tract in women most 
likely occurs by an ascending route from the vagina, 
where GBS can persist asymptomatically. Although in 
treatment of urinary tract infections by GBS is not 
used Erythromycin and Clindamycin routinely, 
whereas source of urinary tract infections can be GBS 
colonization in gastrointestinal or genital tracts, 




Since the clinical significance of inducible 
Clindamycin resistance among all β-hemolytic 
streptococci is unclear, it may not be necessary to 
perform this induction test on all isolates that are 
Erythromycin resistant and Clindamycin susceptible; 
however, all isolates from invasive infections should 
be tested. When a Group B streptococcus is isolated 
from a pregnant woman with severe Penicillin allergy, 
Table 1: Result of antimicrobial susceptibility test by Clindamycin and Erythromycin disks. 
 
Number of samples detected 
as Group B β-hemolytic 
streptococcus 
Erythromycin (%) Clindamycin (%) 
susceptible intermediate resistance susceptible intermediate resistance 
104 samples 55.8% 23% 21.2% 72.2% 4.8% 23% 
 
Table 2: Result of The double disk diffusion test for inducible Clindamycin resistance (phenotypes). 
 
Number of samples 








104 samples 9.5% 10.5% 1% 
 
Frouhesh-Tehrani et al.    Assessment of Clindamycin and Erythromycin Resistance, and Inducible Clindamycin Resistance … 
NBM                                                                            82                                   Novelty in Biomedicine 2015, 2, 79-83 





Streptogramin B (MLSB) phenotype was identified 
by a disc diffusion method
14
. The constitutive MLSB 
(cMLSB) phenotype is associated with high 
resistance to Erythromycin and Clindamycin, in our 
study it obtained 10.5% in total GBS isolated. The 
inducible MLSB (iMLSB) phenotype is associated 
with resistance to Erythromycin and susceptibility to 
Clindamycin, with antagonism between the 
Erythromycin and Clindamycin discs (with positive 
D zone test), in our study it obtained 9.5% in total 
GBS isolated. The M phenotype is determined by 
resistance to Erythromycin, susceptibility to 
Clindamycin and no antagonism between the two 
discs (without D zone test), in our study it obtained 
1% in total GBS isolated. Resistance to 
Erythromycin and inducible Clindamycin resistance 
show limitation of Clindamycin usage when there is 
a resistance to Erythromycin
15
. 
Various studies in other countries report different 
prevalence of inducible Clindamycin resistance, for 
example, in Turkey in 2003 of 156 isolates S. 
agalactiae collected, 28 isolates (18%) expressed the 
iMLS phenotype and 7 isolates (4.5%) expressed the 
cMLS phenotype
10
. in Canada in 2004, Among the 
338 GBS isolates tested, 55 (17%) and 26 isolates 
(8%) were resistant to erythromycin and clindamycin, 
respectively. Of the 55 erythromycin-resistant isolates, 
26 isolates (8%) had constitutive MLSB resistance and 
22 isolates (6.5%) had an inducible MLSB resistance 
phenotype 
16
. between 1997 and 1999 in two Health 
Authority Areas in Móstoles and Granada, Spain of 
221 Streptococcus agalactiae isolated, 185 isolates 
(83.7%) were susceptible to erythromycin and 
azithromycin and 191 isolates (86.4%) were 
susceptible to miocamycin and clindamycin and 23 
isolates (10.4%) had a constitutive MLSB phenotype 
and 7 isolates (3.2%) had an inducible phenotype
17
. In 
Massachusetts in the USA between January 2002 and 
April 2003, of the 200 isolates of GBS, 44 isolates 
(22%) were resistant to erythromycin. 32 isolates 
(16%) were resistant to erythromycin but susceptible 
to clindamycin. Of these isolates, 21 isolates (10.5%) 
had increased clindamycin resistance upon induction 
with erythromycin as determined by the D test and 
There were 11 erythromycin-resistant, clindamycin-
susceptible isolates which did not have inducible 
resistance to clindamycin in this test
18
. In Poland in 
2010, among 169 GBS isolates detected, 27 isolates 
(16%) were resistant to erythromycin and 17(10%) 
resistant to clindamycin. 17 isolates (10%) isolates had 
a cMLSB phenotype and 7 isolates (4%) isolates had 
an iMLSB phenotype
19
. In July 2009, in a laboratory 
in Louisiana, USA, performed routine susceptibility 
testing of GBS isolates. Between 1 July 2009 and 31 
December 2010, 544 GBS isolates were identified, 
 
 








Figure 3. M phenotype 
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with 283 (52%) and 178 (33%) demonstrating 
Erythromycin and Clindamycin resistance, 
respectively. The highest reported rate of inducible 
Clindamycin resistance was 11%
20
. In this way, 
prevalence of inducible Clindamycin resistance in S. 
agalactiae in other studies were 2% in New Zealand 
in 2004, 2% in Australasia in 2005, 2.4% in France 




Various studies in other countries report lower rates 
of inducible Clindamycin resistance. Also rate of 
resistance to Erythromycin and Clindamycin in 
Group B Streptococcus isolates was relatively high in 
this research. These results are may be due to use of 
more macrolides in the treatment of UTI in our 
country.  
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